EGFR testing with liquid biopsy
■EGFR mutation in NSCLC
Activating mutations in the gene encoding EGFR occur primarily in non-
small cell lung cancer (NSCLC), and result in constitutive activation of
the kinase activity of the EGFR protein, thereby contributing to the
oncogenic process. The prevalence of these mutations in unselected
cases of NSCLC is approximately 30%-40% of Asian populations. Several
reports indicate that EGFR mutations can be detected in plasma or
serum of NSCLC patients.
■ FDA approves first liquid biopsy test for EGFR mutations in NSCLC
The cobas® EGFR Mutation Test v2 companion diagnostic looks for small
fragments of circulating tumour DNA (ctDNA) in the patient's
bloodstream, which allows a diagnosis just using a blood sample. This
enables patients to avoid an invasive tissue biopsy when their lung
cancer progresses after first-line treatment with an EGFR-TKI.
The advantages of liquid biopsy
Only blood drawn, suitable for too unhealthy for tissue biopsy.
Liquid biopsy techniques capable of capturing tumor heterogeneity and the molecular changes cancer cells undergo when they are exposed to
therapy are needed.
There are rapid increases in ctDNA levels with disease progression and
corresponding declines in levels after successful treatment with
pharmacologic therapy or resective surgery.
Step1. Consulting with physician to understand the test content
Step2. Go hospitals to collect specimen and fill out the consent form
Step3. Send specimen to SOFIVA lab
Step4. DNA extraction and analysis
Step5. The report will be provided in 5 business days
*You should consult with your physician.